QPPV.COM KNOWLEDGE ASSESSMENT

Bictegravir: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Bictegravir: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the evidence from the phase III switch studies?
Question 2 of 10 A person with HIV and hepatitis B stops the fixed-dose regimen and subsequently develops a hepatitis flare. Which explanation should be prioritised in the assessment?
Question 3 of 10 A reviewer compares the phase II bictegravir dose with the authorised adult combination dose. Which interpretation is correct?
Question 4 of 10 A medication review identifies rifampin in a patient taking Biktarvy. Which interpretation matches the US product information described in the article?
Question 5 of 10 A spontaneous-report database contains an increasing number of renal reports for the combination. What is the most appropriate signal-evaluation interpretation?
Question 6 of 10 A reviewer is preparing an EU eligibility assessment using information from the US label. Which approach is most appropriate?
Question 7 of 10 A clinician asks whether metformin must be stopped when Biktarvy is started. Which response best reflects the interaction information in the article?
Question 8 of 10 How should a potential interaction with rifabutin or rifapentine be distinguished from the rifampin interaction in the article?
Question 9 of 10 Which description most accurately characterises the QPPV's role in the pharmacovigilance system described in the article?
Question 10 of 10 A patient has detectable viraemia while taking the regimen. Which interpretation is most appropriate for evaluating a suspected lack-of-efficacy event?

Select an answer to continue.

QPPV.com